Answers are grounded in this paper and cite their sources.
The 2018 and 2019 guidelines from the American College of Cardiology and American Heart Association reflect the complexity of individualized cholesterol management. The documents address more detailed risk assessment, newer nonstatin cholesterol-lowering drugs, special attention to patient subgroups, and consideration of the value of therapy, all with the aim of creating personalized treatment plans for each patient. Overall, the guidelines recommend shared decision-making to meet the individual needs of each patient.
No takes yet. Share an insight, caveat, or question.
Reiter–Brennan et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: